MiMedx Group (MDXG) Q2 2025 Earnings Call July 30, 2025 04:30 PM ET Speaker0Good afternoon, and thank you for standing by. Welcome to the Mimetics Second Quarter twenty twenty five Operating and Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded.I would now like to turn the conference over to Mr. Matt Matoriani, Head of Investor Relations for Mimetics. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ____________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2025 MIMEDX GROUP, INC. (Exact name of registrant as specified in charter) Florida 001-35887 26-2792552 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 1775 West Oak Commons Ct., NE, Marietta GA 30062 (Address ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Securities regist ...

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact: Matt Notari ...

Core Insights - The Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement mechanism for skin substitutes, moving from the Average Sales Price (ASP) methodology to a fixed price of $125.38 per square centimeter [2][3] - The skin substitute market has seen a significant increase in Medicare spending, rising from approximately $1.5 billion in 2022 to nearly $10 billion in 2024, highlighting the need for reimbursement reform to combat fraud, waste, and abuse [3] Company Positioning - MiMedx Group, Inc. supports the proposed reimbursement changes and believes that reform is necessary to restore rational market behavior and benefit stakeholders, taxpayers, and patients [2][3] - The company is well-positioned to thrive in an environment where product capabilities, backed by strong clinical evidence, influence selection and usage [3] Upcoming Developments - The Wasteful and Inappropriate Service Reduction (WISeR) model, Local Coverage Determinations (LCDs), and the Physician Fee Schedule (PFS) rules are set to be implemented on January 1, 2026 [3] - The Hospital Outpatient Prospective Payment System (OPPS) is also expected to be released in proposed form, with implementation slated for January 1, 2026 [4]

Company Overview - MiMedx (MDXG) shares increased by 8% in the last trading session, closing at $7, with higher trading volume compared to normal sessions [1] - The stock has shown a 0.5% gain over the past four weeks [1] - The rise in stock price is linked to investor optimism regarding the company's product portfolio in wound care, burn, and surgical sectors [1] Financial Performance - MiMedx is expected to report quarterly earnings of $0.06 per share, reflecting a year-over-year decline of 25% [2] - Revenue projections for the upcoming quarter are $89.28 million, which is a 2.4% increase from the same quarter last year [2] Earnings Estimates and Stock Movement - The consensus EPS estimate for MiMedx has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] - Historical data suggests that stock prices typically do not continue to rise without trends in earnings estimate revisions [3][4] Industry Context - MiMedx operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like PTC Therapeutics (PTCT) [5] - PTC Therapeutics has experienced a 0.7% decline in its stock price, with a return of -7.2% over the past month [5] - The consensus EPS estimate for PTC Therapeutics has decreased by 0.4% to -$1.07, representing a 7.8% increase from the previous year [6]

Investor Presentation – May 2025 2 • Growing expansion outside of the U.S.; • Our growth expectations in 2025 and beyond, including our growth in surgery, increased funding in targeted research and expandedproduct portfolio; • Expected results of research and development, including that our efforts will innovate and diversify our product portfolio; • Placental-derived products and their potential clinical benefits; • Expectations regarding the reimbursement environment for the Company's products, including ...

Company Overview - MiMedx Group, Inc. is a pioneer and leader in the healthcare sector focused on healing solutions, particularly for chronic and hard-to-heal wounds [2] - The company aims to be the leading global provider of healing solutions through relentless innovation to restore quality of life [2] Upcoming Investor Conferences - MiMedx will participate in the Craig-Hallum 22nd Annual Institutional Investor Conference on May 28, 2025, in Minneapolis, MN, with 1:1 sessions [1] - The company will also attend the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, in Miami, FL, with 1:1 sessions [1] - Additionally, MiMedx will be part of the Northland Capital Growth Conference on June 25, 2025, which will be held virtually, also featuring 1:1 sessions [1]

MiMedx Group (MDXG) 2025 Conference May 13, 2025 08:15 PM ET Speaker0 On the wound care front, our products are found in virtually every care setting where a patient presents with a chronic or hard to heal wound, and there are lots of them as you can see from this slide. Our portfolio is comprised of a number of products, but I'd like to focus on a few highlights from our portfolio for a moment. First up, EpiFix is our flagship product for the wound market, and as I mentioned, most widely recognized efficac ...

Core Insights - MiMedx reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, but down from $0.07 per share a year ago [1] - The company generated revenues of $88.21 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.56% and up from $84.71 million year-over-year [2] - MiMedx shares have declined approximately 28.1% year-to-date, contrasting with the S&P 500's decline of 5.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $93.5 million, and for the current fiscal year, it is $0.29 on revenues of $375 million [7] - The estimate revisions trend for MiMedx is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which MiMedx belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Alnylam Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.56 per share, reflecting a significant year-over-year decline of 250% [9]